Plain-English translation of NCT06669013 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , an immunotherapy medication, combined with chemotherapy for children and teenagers under 18 whose bone or soft tissue sarcomas have grown or spread despite their initial chemotherapy treatment. The study focuses on three types of sarcomas: rhabdomyosarcoma, Ewing's sarcoma, and osteosarcoma. Researchers want to see if adding this medication to chemotherapy can help stop or slow down these aggressive cancers.
These types of sarcomas are difficult to treat once they stop responding to the first round of chemotherapy, and children with relapsed or resistant disease need new options. This trial explores whether this medication can harness the immune system to help fight the cancer when standard chemotherapy alone is no longer working.
You likely qualify if…
You likely don't qualify if…
You would receive 6 cycles of the new immunotherapy medication through an IV infusion, combined with 6 to 8 cycles of chemotherapy. The chemotherapy regimen would be chosen by your doctor based on your sarcoma type. Your doctor will check how well the treatment is working after 2 cycles, 4 cycles, and at the end of treatment using imaging scans. After you finish treatment, you'll have follow-up visits every month to check your health and how long you survive, continuing for as long as possible unless you choose to withdraw.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
Russia